Form 4: Lexaria Bioscience Corp. Director Acquires 5,000 Stock Options
SEC Form 4 Filing
William Edward McKechnie, a director of Lexaria Bioscience Corp., reports the acquisition of 5,000 stock options.
Summary
- On April 26, 2024, William Edward McKechnie, a director of Lexaria Bioscience Corp., acquired 5,000 stock options with an exercise price of $2.36.
- These options are exercisable from April 26, 2024, and expire on April 26, 2029.
- Following this transaction, McKechnie beneficially owns 40,000 stock options.
- McKechnie also directly owns 13,191 common shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, reflecting a neutral sentiment. It simply reports a transaction.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The details provided are consistent with SEC regulations and reporting requirements.
- Comparable companies like Canopy Growth Corporation or Aurora Cannabis would have similar filings when their directors trade company stock.
Stakeholder Impact
- The transaction provides shareholders with information about insider activity, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date exercisable for 1,500 stock options at $3.00, expiring 04/26/2026 |
| 06/08/2021 | Date exercisable for 5,000 stock options at $3.00, expiring 06/08/2026 |
| 09/01/2021 | Date exercisable for 1,900 stock options at $3.00, expiring 09/01/2026 |
| 03/08/2022 | Date exercisable for 3,400 stock options at $3.39, expiring 03/08/2027 |
| 10/12/2022 | Date exercisable for 18,200 stock options at $1.96, expiring 10/12/2027 |
| 07/25/2023 | Date exercisable for 5,000 stock options at $0.87, expiring 07/25/2028 |
| 04/26/2024 | Date of transaction and date exercisable for 5,000 stock options at $2.36, expiring 04/26/2029 |
| 05/09/2023 | Shareholder approval received to reprice stock options |
| 05/10/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.